Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket

You may also be interested in...

GSK Pumps In $1 Billion To Raise Equity In Indian Pharma Subsidiary

GSK said it will infuse $1 billion to purchase shares and raise its stake in its Indian arm to 75%, the highest limit allowed in India. Brushing aside the growth setback in the last few months, the British firm reaffirmed a long view of the Indian health care market.

Eisai Brings Halaven To India With A Tiered-Pricing Strategy

The Japanese drug firm is making a strong bid to make expensive drugs affordable in emerging markets like India. For those who cannot pay, the drug will be made available free of charge.

GSK India Saves Tykerb Main Patent But Loses Claims On Salt Patent To Fresenius Kabi

Amid a series of patent related setbacks faced by global drug firms, GSK has safeguarded Tykerb against Fresenius Kabi.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts